Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party. The US-based company received the PRV when its Niemann-Pick disease type C drug Miplyffa (arimoclomol) won FDA approval in September 2024.

For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that keeps on giving. | After receiving a rare pediatric disease priority review voucher in tandem with Miplyffa’s FDA green light in September,

Timothy J. Sangiovanni, Senior Vice President of Finance and Corporate Controller at Zevra Therapeutics Inc. (NASDAQ:ZVRA), has sold 3,000 shares of the company's common stock. The shares were sold at an average price of $7.